Curated News
By: NewsRamp Editorial Staff
September 02, 2026
Tonix Pharmaceuticals to Present at Cantor's 2026 Healthcare Conference
TLDR
- Tonix Pharmaceuticals' CEO presents at Cantor's 2026 conference, showcasing TONMYA's market edge and pipeline advances, offering investors a potential advantage.
- Tonix Pharmaceuticals details its integrated CNS and immunology pipeline, including TONMYA for fibromyalgia and TNX-1500 for kidney transplant rejection, at the conference.
- Tonix Pharmaceuticals aims to improve lives with new treatments for fibromyalgia, depression, and rare diseases, addressing unmet medical needs.
- Tonix Pharmaceuticals introduces TONMYA, the first new fibromyalgia drug in 15 years, and explores its use for other conditions.
Impact - Why it Matters
This news matters because Tonix Pharmaceuticals is pushing the boundaries of treatment for fibromyalgia and other CNS disorders. The approval of TONMYA™ represents a breakthrough for patients who have had limited options for over a decade. Moreover, the company's pipeline, including potential treatments for depression, PTSD, Lyme disease, and transplant rejection, could significantly impact public health. Investors and patients alike should monitor Tonix's progress as it navigates clinical trials and commercial expansion, potentially reshaping therapeutic landscapes and offering new hope for millions.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP), a fully-integrated commercial-stage biotech company, is set to make a significant appearance at Cantor’s 2026 Global Healthcare Conference in New York from September 9-11. President and CEO Seth Lederman, M.D., will participate in a fireside chat on September 10 from 3:55-4:25 p.m. ET, with a live webcast and replay accessible via the Investors section of the Tonix website. The company will also engage in one-on-one meetings, underscoring its commitment to investor relations and transparency.
Tonix has recently achieved a major milestone with the approval of TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. This flagship medicine is now the cornerstone of the company's CNS commercial infrastructure, which also includes acute migraine products Zembrace® SymTouch® and Tosymra®. Tonix is actively exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder, expanding its therapeutic reach. Beyond CNS, the pipeline includes TNX-2900 for Prader-Willi syndrome (Phase 2 ready), TNX-4800 for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for kidney transplant rejection prevention. These candidates highlight Tonix's focus on high unmet medical needs in both CNS and immunology.
Investors can stay updated via the company's newsroom at https://nnw.fm/TNXP. The full press release is available at https://nnw.fm/hajiz. Tonix's participation in such a prestigious conference underscores its growing prominence in the biotech sector, and its innovative pipeline promises to address critical health challenges.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals to Present at Cantor's 2026 Healthcare Conference
